FDA/CDC

Cannabis: Doctors tell FDA to get out of the weeds


 

FROM AN FDA PUBLIC HEARING

The way forward

A variety of regulatory pathways were proposed at the hearing. To prevent adulteration and contamination issues, many advocated standardized good manufacturing practices (GMPs), product reporting, and identification or registration, and a centralized reporting registry for adverse events.

Patient advocates, physicians, and scientists called for an easing of access to cannabis for medical research. Currently, cannabis, still classified as a Schedule I substance by the Drug Enforcement Administration, is only legally available for this purpose through a supply maintained by the National Institute on Drug Abuse. A limited number of strains are available, and access requires a lengthy approval process.

Most discussion centered around CBD, though some presenters asked for smoother sailing for THC research as well, particularly as a potential adjunct or alternative to opioids for chronic pain. Cannabidiol has generally been recognized as non-psychoactive, and the FDA assigned it a very low probability of causing dependence or addiction problems in its own review of human data.

However, in his opening remarks, Dr. Sharpless warned that this fact does not make CBD a benign substance, and many questions remain unanswered.

“How much CBD is safe to consume in a day? What if someone applies a topical CBD lotion, consumes a CBD beverage or candy, and also consumes some CBD oil? How much is too much? How will it interact with other drugs the person might be taking? What if she’s pregnant? What if children access CBD products like gummy edibles? What happens when someone chronically uses CBD for prolonged periods? These and many other questions represent important and significant gaps in our knowledge,” said Dr. Sharpless.

The FDA has established a public docket where the public may submit comments and documents until July 2, 2019.

Pages

Recommended Reading

Common AEDs confer modestly increased risk of major congenital malformations
MDedge Pediatrics
How does CBD compare and interact with other AEDs?
MDedge Pediatrics
Hippocampal abnormalities seen in epilepsy subtypes may be congenital
MDedge Pediatrics
Prenatal valproate exposure raises ADHD risk
MDedge Pediatrics
Onset of pediatric status epilepticus may have a circadian pattern
MDedge Pediatrics
FDA approves generic version of vigabatrin
MDedge Pediatrics
FDA concerned about e-cigs/seizures in youth
MDedge Pediatrics
Postvaccination febrile seizures are no more severe than other febrile seizures
MDedge Pediatrics
Angelman syndrome treatment safe, well-tolerated, and effective in exploratory analyses
MDedge Pediatrics
Cannabidiol reduces seizures in Dravet syndrome
MDedge Pediatrics